Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Oct 8;429:119804. doi: 10.1016/j.jns.2021.119804

Prolonged cognitive deficits after COVID-19

Michelangelo Dini a, Elisabetta Groppo a, Rosci Chiara a, Maria Reitano a, Elisa Allocco a, Agostino Brugnera b, Barbara Poletti c, Antonella D'Arminio Monforte d, Davide Chiumello e, Stefano Centanni f, Vincenzo Silani c,g, Alberto Priori a, Roberta Ferrucci a
PMCID: PMC8498312

Background and aims

Cognitive deficits are a common complication of COVID-19. Multiple factors associated with the illness and its treatment may contribute to cognitive deficits. In this study, we analysed neuropsychological data from a cohort of patients recovering from COVID-19 hospitalization who required different types of oxygen/ventilation therapy.

Methods

We recruited 77 (aged 22–77 years; 57 males) patients hospitalized for complications of SARS-CoV-2 infection in different COVID units, which had required different oxygen (O2) therapy (no-O2  = 9, low-flow O2  = 35, CPAP = 26, intubation = 7). Participants underwent neuropsychological testing with the Brief Repeatable Battery of Neuropsychological Tests (BRB-NT) about 5 months after hospital discharge.

Results

Of all participants, 64% showed deficits in at least one test of the BRB-NT; the most affected functions were processing speed (41.6% of participants) and delayed verbal recall (27.3%).

O2 therapy with CPAP was associated with worse verbal memory performance (p = 0.033), compared to no-O2 therapy. Attention and processing speed deficits were not associated with type of O2 therapy (p = 0.889), but correlated with thromboplastin (aPTT) ratio (rs = 0.298, p = 0.019).

Worse delayed visuospatial recall was associated with hyposmia (p = 0.011) and dysgeusia (p = 0.035).

Conclusions

Cognitive deficits are frequent, persistent, and disabling even for five months following hospitalization for COVID-19. Therefore, neurological and neuropsychological monitoring should be put in place after discharge to help mitigate the effects of these symptoms, improving the quality of life of COVID-19 survivors.


Articles from Journal of the Neurological Sciences are provided here courtesy of Elsevier

RESOURCES